Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APHRODITE trial of mitazalimab for prevention of malignant transformation in high-risk oral potentially malignant disorders
2025-521490-13-00Phase 2Authorised
- Sponsor
- Humanitas Research Hospital
- Start
- Jul 2025
- Modality
- Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mitazalimab in oral premalignancies, sponsored by Humanitas Research Hospital. Primary endpoint: Best overall response rate at 6 months. Planned start Jul 2025; status: authorised.
02
Drugs
mitazalimab
03
Conditions
oral premalignancies
Beyond the preview
Go deeper on 2025-521490-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521490-13-00.